Skip to main content

Table 2 Efficacy of telbivudine treatment

From: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation

 

Telbivudine

(N = 139)

Control

(N = 102)

P value

HBV DNA, log10 IU/mL, median (range)

 Week 2

5.51 (3.04–8.06)

7.74 (6.03–9.00)

< 0.001

 Week 4

4.12 (2.70–7.43)

7.70 (6.03–9.00)

< 0.001

 Week 8

3.20 (2.70–6.76)

7.74 (6.03–9.00)

< 0.001

 At delivery

2.82 (2.70–6.45)

7.72 (5.32–9.00)

< 0.001

ALT levels at delivery, U/L, median (range)

28 (11–238)

47 (8–217)

< 0.001

Normalization rate of ALT, n (%)

105 (75.5%)

52 (51%)

< 0.001

AST levels at delivery, U/L, median (range)

27 (11–141)

39 (17–144)

< 0.001

Normalization rate of AST, n (%)

112 (80.6%)

55 (53.9%)

< 0.001

TBIL levels at delivery, U/L, median (range)

1.1 (9.8–36.0)

9.5 (3.8–48.6)

0.459

Normalization rate of TBIL, n (%)

137 (98.6%)

100 (98.0%)

1.000

HBeAg positive at delivery, n (%)

108 (77.7%)

91 (89.2%)

0.025